Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 455.81K | 95.67%-1.41M | -99.39%61.21K | -97.60%293.86K | -85.24%1.51M | 0 | -437.07%-32.48M | -15.73%10.04M | -41.20%12.22M | -20.31%10.21M |
Operating revenue | --455.81K | 95.67%-1.41M | -99.39%61.21K | -97.60%293.86K | -85.24%1.51M | --0 | -437.07%-32.48M | -15.73%10.04M | -41.20%12.22M | -20.31%10.21M |
Cost of revenue | 277.29K | 94.82%-1.5M | -99.65%31.34K | -97.62%261.43K | -83.65%1.48M | 0 | -440.82%-28.91M | -14.44%8.87M | -43.68%10.97M | -26.56%9.07M |
Gross profit | 178.51K | 102.56%91.16K | -97.44%29.87K | -97.41%32.43K | -97.81%25.05K | 0 | -409.47%-3.56M | -24.37%1.17M | -4.27%1.25M | 145.02%1.14M |
Operating expense | 82.76%3.91M | -214.92%-292.38K | 253.50%2.48M | 28.21%883.23K | -0.06%842.29K | 127.25%2.14M | -112.89%-92.84K | 213.10%700.78K | 83.39%688.9K | 81.27%842.83K |
Selling and administrative expenses | 79.00%3.83M | 934.51%774.77K | 93.96%1.36M | 25.52%864.7K | -1.36%831.4K | -6.23%2.14M | -112.89%-92.84K | -2.77%700.78K | 83.39%688.9K | 81.27%842.83K |
-Selling and marketing expense | ---- | ---- | -89.37%19.56K | -86.26%19.42K | -90.54%20.61K | ---- | ---- | -31.78%184.06K | 2,074.02%141.34K | 4.74%217.78K |
-General and administrative expense | 79.00%3.83M | 137.46%795.56K | 159.26%1.34M | 54.37%845.27K | 29.72%810.79K | 36.88%2.14M | -29.09%335.02K | 14.60%516.72K | 43.03%547.56K | 143.18%625.05K |
Depreciation amortization depletion | --80.33K | --27.95K | --22.95K | --18.54K | --10.89K | --0 | --0 | --0 | --0 | --0 |
-Depreciation and amortization | --80.33K | --27.95K | --22.95K | --18.54K | --10.89K | --0 | --0 | --0 | --0 | --0 |
Provision for doubtful accounts | ---- | ---- | --1.1M | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
Operating profit | -74.41%-3.73M | 111.05%383.54K | -624.54%-2.45M | -250.99%-850.8K | -372.21%-817.24K | -160.65%-2.14M | -905.64%-3.47M | -78.43%466.58K | -39.57%563.47K | 19,096.10%300.23K |
Net non-operating interest income expense | 433.21%275.86K | -75.33%251.32K | 124.07%72.08K | 89.30%-37.75K | 85.22%-66.96K | 96.67%-82.79K | 426.81%1.02M | 51.17%-299.46K | 57.42%-352.7K | 38.45%-453.08K |
Non-operating interest income | 3,124.71%320.47K | 2,848.91%174.84K | 82,571.96%88.46K | ---- | --242 | --9.94K | --5.93K | --107 | ---- | --0 |
Non-operating interest expense | -14.16%35.95K | 92.31%-77.88K | -94.79%14.87K | -89.10%36.2K | -85.58%63.01K | -98.28%41.88K | -438.51%-1.01M | -53.02%285.24K | -59.50%332.01K | -38.74%436.89K |
Total other finance cost | -82.97%8.66K | 485.71%1.4K | -89.43%1.52K | -92.53%1.55K | -74.09%4.2K | 1.19%50.84K | -102.88%-364 | 132.69%14.33K | 144.13%20.69K | -29.54%16.19K |
Other net income (expense) | -63.02%8.01K | 7.2K | 36 | 1,342.73%28.39K | 1,428.02%29.55K | 66.91%21.66K | -7.78%1.97K | -8.43%1.93K | ||
Other non- operating income (expenses) | -63.02%8.01K | --7.2K | --36 | 1,342.73%28.39K | 1,428.02%29.55K | 66.91%21.66K | ---- | ---- | -7.78%1.97K | -8.43%1.93K |
Income before tax | -56.67%-3.45M | 126.42%642.06K | -1,521.30%-2.38M | -504.32%-860.16K | -466.29%-854.64K | -309.31%-2.2M | -2,051.73%-2.43M | -89.24%167.12K | 100.03%212.74K | 79.40%-150.92K |
Income tax | 55.86%-215.82K | 253.00%837.15K | -1,366.44%-559.98K | -533.84%-247.28K | -471.59%-245.71K | -308.51%-488.92K | -1,115.56%-547.14K | -86.76%44.22K | 132.18%57K | 75.82%-42.99K |
Net income | -3,976.04%-5.19M | -5,740.01%-2.15M | -1,577.01%-1.82M | -493.52%-612.88K | -464.17%-608.93K | -83.61%133.87K | -152.18%-36.85K | -89.92%122.9K | 90.39%155.75K | 80.54%-107.93K |
Net income continuous Operations | -88.81%-3.23M | 89.64%-195.09K | -1,577.01%-1.82M | -493.52%-612.88K | -464.17%-608.93K | -309.54%-1.71M | -2,765.97%-1.88M | -89.92%122.9K | 90.39%155.75K | 80.54%-107.93K |
Net income discontinuous operations | -206.01%-1.96M | ---- | ---- | ---- | ---- | --1.85M | ---- | ---- | ---- | ---- |
Minority interest income | ||||||||||
Net income attributable to the parent company | -3,976.04%-5.19M | -5,740.01%-2.15M | -1,577.01%-1.82M | -493.52%-612.88K | -464.17%-608.93K | -83.61%133.87K | -152.18%-36.85K | -89.92%122.9K | 90.39%155.75K | 80.54%-107.93K |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | -3,976.04%-5.19M | -5,740.01%-2.15M | -1,577.01%-1.82M | -493.52%-612.88K | -464.17%-608.93K | -83.61%133.87K | -152.18%-36.85K | -89.92%122.9K | 90.39%155.75K | 80.54%-107.93K |
Basic earnings per share | -2,308.33%-2.65 | -1,931.54%-0.6685 | -1,063.64%-16.96 | -445.10%-0.48 | -397.98%-0.48 | -83.55%0.12 | -152.18%-0.0329 | 61.64%1.76 | 90.39%0.1391 | 80.54%-0.0964 |
Diluted earnings per share | -2,308.33%-2.65 | -1,931.54%-0.6685 | -1,063.64%-16.96 | -445.10%-0.48 | -397.98%-0.48 | -83.55%0.12 | -152.18%-0.0329 | 61.64%1.76 | 90.39%0.1391 | 80.54%-0.0964 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |